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Abstract
Background Correction of low hemoglobin (Hb) levels is
associated with improved survival and greater quality of
life in dialysis patients, but frequent administration of
erythropoiesis stimulating agent (ESA) therapy is unsatis-
factory for peritoneal dialysis patients.
Objective The objective of this study was to assess Hb
stability in an unselected population of maintenance perito-
neal dialysis patients receiving once-monthly treatment with
C.E.R.A., a continuous erythropoietin receptor activator.
Methods In a prospective, non-interventional, single-arm
study at 33 Germany dialysis centers, peritoneal dialysis
patients with or without ESA treatment prior to study entry
received once-monthly treatment with C.E.R.A. Hb sta-
bility was assessed by the proportion of patients for whom
all measured Hb values during months 6–8 (the evaluation
phase) were within the range 11–12, 11–13, 10–12 or
11–12.5 g/dL.
Results 220 patients received at least one dose of C.E.R.A.
During the evaluation phase, 185 patients provided C1 Hb
measurement (efficacy population) and 162 patients pro-
vided C2 Hb measurements (the modified efficacy
population). The mean (SD) time between C.E.R.A. doses
was 28.2 (7.2) days and mean (SD) C.E.R.A. dose was 109
(57) lg per application. Mean (SD) Hb level was 11.1
(1.4) g/dL at baseline and 11.5 (1.3) g/dL at the end of the
study (modified efficacy population). The primary efficacy
variable, all measured Hb values in the range 11–12 g/dL,
was 18.4 % (34/185) and 14.8 % (24/162) in the efficacy
and modified efficacy populations, respectively. The mean
(SD) maximum intra-individual fluctuation in Hb level was
0.56 (0.50) g/dL in the efficacy population and 0.58
(0.49) g/dL in the modified efficacy population, with max-
imum intra-individual fluctuation B1 g/dL in 85.4 % (158/
185) and 83.3 % (135/162) of patients, respectively. No
adverse drug reactions were reported during the study.
Conclusion In this large population of maintenance per-
itoneal dialysis patients, once-monthly administration of
C.E.R.A. achieved a high degree of Hb stability and was
well-tolerated.
1 Introduction
Anemia is a well-recognized complication of end-stage
renal disease, arising from inadequate production of
erythropoietin by the failing kidney in response to declin-
ing hemoglobin (Hb) concentration. By the time dialysis is
required, approximately three-quarters of patients are
anemic [1]. In addition to the classic symptom of fatigue
[2], the presence of anemia in patients with peritoneal
dialysis contributes to increased cardiovascular risk [3],
increased insulin resistance [4] and risk of mortality [5]. An
analysis of data from almost 14,000 peritoneally dialyzed
patients demonstrated that Hb levels below 11.0 g/dL, and
particularly levels less than 10 g/dL, were associated with a
higher risk of both hospitalization and mortality [5].
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Observational evidence that correction of low Hb levels is
associated with improved survival in dialysis patients [6],
as well as greater quality of life [7], has led to recom-
mendations that a Hb level of 11–12 g/dL should be tar-
geted in dialysis patients receiving erythropoiesis
stimulating agent (ESA) therapy, with the aim of not
exceeding 13 g/dL [8]. More recently, the Kidney Disease:
Improving Global Outcomes (KDIGO) guidelines have
proposed that ESA maintenance therapy not be used to
maintain Hb levels above 11.5 g/dL in adult patients with
CKD, and recommend that ESAs not be used to inten-
tionally increase Hb above 13.0 g/dL [9].
Since the introduction of recombinant human erythro-
poietin preparations in 1989, the previously widespread
problem of severe anemia in end-stage renal disease had
been largely overcome. However, such therapies have a
relatively short half-life, requiring administration as often
as twice or three times a week. For the peritoneal dialysis
patient this necessitates regular clinical visits or frequent
self-injection at home, which is both unsatisfactory and can
affect compliance. Darbepoetin alfa, which has a somewhat
longer half-life than epoetin alfa or beta (*25 h [10]
compared to B9 h [11]) and is routinely used once a week,
has been assessed for once-monthly dosing in peritoneal
dialysis patients in small non-comparative series, but was
not always adequate to maintain Hb levels [12–14].
The pharmacokinetic characteristics of the continuous
erythropoietin receptor activator C.E.R.A., including a long
half-life (*130 h), a relatively low binding affinity for the
erythropoiesis receptor and low systemic clearance [15],
permit once-monthly dosing. The efficacy of once-monthly
C.E.R.A. in hemodialysis patients is similar to shorter-act-
ing ESA agents in terms of maintaining Hb levels [16–18].
Clinical experience in hemodialysis patients suggests that
conversion from more frequently administered ESA thera-
pies to once-monthly C.E.R.A. is convenient and maintains
good control of Hb levels [19, 20]. Results from the
hemodialysis setting, however, are not necessarily applica-
ble to peritoneal dialysis patients. Anemia control with ESA
therapy appears to be more readily achieved in peritoneal
dialysis patients than in patients receiving hemodialysis
[21–25]. A large analysis of US Medicare data from
1995–2000 showed that although ESA therapy was much
less frequent in peritoneal dialysis patients (25 versus 80 %
of hemodialysis patients), with 50 % lower doses, Hb levels
were similar between the two groups [23]. Similarly, a
multicenter comparative study in France observed that mean
Hb levels were similar in the peritoneal dialysis or hemod-
ialysis subpopulations but that this was achieved in the
peritoneally dialyzed patients with a significantly lower dose
of ESA at a lower frequency of administration, and with a
reduced rate of intravenous iron therapy [24]. In routine
practice, both ESA dose [24–26] and use of intravenous iron
[24, 27] is often lower in peritoneal dialysis patients com-
pared to the hemodialysis population. Several factors may be
involved in the difference in anemia control between dial-
ysis modalities. Better depuration of erythropoiesis inhibi-
tors during peritoneal dialysis, superior preservation of
residual renal function, absence of blood loss from hemod-
ialysis sessions, and greater adequacy of dialysis in terms of
frequency and duration may all play a role [28, 29] although
their relative contributions are difficult to determine.
The present study was a prospective, multicenter,
observational trial undertaken to assess Hb stability in an
unselected population of maintenance peritoneal dialysis
patients receiving C.E.R.A. therapy once a month.
2 Methods
2.1 Study Design and Conduct
This was a prospective, non-interventional, single-arm
study conducted at 33 nephrology centers in Germany
during the period April 2009 to March 2011. Following
enrolment, all patients received C.E.R.A. therapy once a
month. The dose of C.E.R.A. was titrated during the first six
months post-baseline (the titration phase), with an evalua-
tion phase during the following three months (months 6–8).
The study was undertaken in accordance with German
Medicines Act, as a non-interventional study. The obser-
vational plan and the informed consent form were
approved by the local ethics committee for the lead
investigator (MK) (A¨rztekammer Nordrhein, Du¨sseldorf).
All study participants provided written informed consent.
Roche Pharma AG (Germany) funded the study, including
data analysis by a contract research association, and
reviewed the manuscript. All data collection was under-
taken by the study investigators.
2.2 Patient Population
Patients were eligible for inclusion if they were receiving
peritoneal dialysis and, in the opinion of the investigator,
required ESA therapy. Patients were required to have a life
expectancy of more than 9 months and to have iron indices
within the limits defined by the European Best Practice
Guidelines (serum ferritin C100 ng/mL and transferrin
saturation (TSAT) C20 %) [30]. Exclusion criteria com-
prised active malignancy, acute infection, acute bleeding,
decrease in Hb level within the 4 weeks prior to inclusion
(as defined by the investigator), and pregnancy. Patients
could be receiving ESA therapy at the time of study entry.
Patients were to be withdrawn from the study if an ESA
agent other than C.E.R.A. was initiated or if hemodialysis
was started.
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2.3 Medication
Prior to study entry, any ESA therapy was administered by
the physician according to local practice and the summary
of product characteristics of the selected ESA. All patients
received C.E.R.A therapy from study entry, prescribed
according to local practice. Dose changes were made at the
discretion of the investigator.
2.4 Data Collection
Study visits took place at study entry and then monthly up to
nine months after the baseline visit. Assessments took place
at routine clinical visits. If a patient discontinued C.E.R.A.
prematurely or started hemodialysis, a final assessment was
carried out but no further data were documented.
At study entry, the following data were collected:
demographics, concomitant disease, cause of end-stage
renal disease, duration of peritoneal dialysis, type of pre-
vious ESA therapy during the preceding 16 weeks if rele-
vant, use of C.E.R.A. during the preceding 16 weeks,
reason for switch to C.E.R.A., current Hb level prior to
C.E.R.A. dose at study entry and laboratory values [iron
status, hematology, liver function, estimated glomerular
filtration rate (eGFR) calculated by the Modification in
Renal Disease (MDRD) formula [31], C-reactive protein,
vitamin B12, renal and peritoneal Kt/V (where K is dialyzer
clearance of urea, t is dialysis time and V is the volume of
distribution of urea), parathyroid hormone and albumin].
At all post-baseline study visits, the following data were
recorded: Hb level prior to C.E.R.A. administration, labo-
ratory values and changes in concomitant disease/medica-
tion. Adverse drug reactions were to be documented,
including duration, severity, whether the event was regar-
ded as serious, and causal relationship with C.E.R.A.
Data were recorded by study investigators on printed
forms or electronically. Printed data entries were sent
directly to an independent clinical research organization
(M.A.R.C.O GmbH & Co KG, 40227 Du¨sseldorf,
Germany), where data were entered to the study database.
Electronic data capture contained the same information as
the printed forms. The clinical research organization was
responsible for clarifying discrepancies on the submitted
forms and obtaining additional information from physi-
cians as necessary.
2.5 Statistical Analysis
All data are presented descriptively with no formal statis-
tical analyses, as planned in the study protocol. Stability of
Hb was assessed by the proportion of patients for whom all
measured Hb values during months 6–8 (the evaluation
phase) were within the range 11–12, 11–13, 10–12 or
11–12.5 g/dL. The maximum intra-individual fluctuation in
Hb values was defined as the maximum absolute difference
from the individual mean Hb value during the evaluation
phase.
The safety population comprised all patients who
received at least one dose of C.E.R.A. The efficacy popu-
lation comprised all patients in the safety population who
provided at least one post-baseline measurement of Hb
concentration. The modified efficacy population consisted
of all patients in the efficacy population for whom at least
two Hb measurements were available during the evaluation
period. A pre-defined subanalysis was performed based on
patients in the efficacy population who did not receive
C.E.R.A. prior to the study. For patients in whom C.E.R.A.
therapy was stopped before the end of the observation
period, data were analyzed to the point of discontinuation.
All analyses were descriptive. Statistical analyses were




A total of 223 patients were enrolled; 220 (98.7 %)
received at least one dose of C.E.R.A. and formed the
safety population. Of these, 219 patients (99.5 %) provided
at least one post-baseline Hb measurement and were
included in the efficacy population: 185 of these patients
provided at least one Hb measurement during the evalua-
tion phase. The modified efficacy population comprised
162/219 patients (74.0 %) (Fig. 1). The nine-month study
was completed by 167/220 patients (75.9 %), with the most
frequent reason for discontinuation being switch to he-
modialysis (Fig. 1).
The mean age of the population was approximately
57 years and slightly more than half the patients (113/220,
51.4 %) were male (Table 1). Concomitant cardiac disor-
ders and diabetes mellitus type 2 were present in 40.9 and
18.1 % of patients, respectively. At time of study entry, the
mean duration of peritoneal dialysis was 3.0 years (range
1–15 years). Most patients (135/220, 61.4 %) were
receiving continuous ambulatory peritoneal dialysis
(CAPD).
Mean (SD) Hb at baseline was 11.1 (1.3) g/dL, with a
median value of 11.1 (range 5.4–15.7 g/dL) in the safety
population. Sixty patients (27.3 %) were receiving oral
iron supplementation and 40 patients (18.2 %) were
receiving intravenous iron; a further four patients (0.2 %)
were receiving unspecified iron preparations. The last post-
baseline values for median serum ferritin and TSAT were
114 ng/mL (n = 160) and 26.9 % (n = 146), respectively.
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In the 16 weeks prior to study entry, 75.9 % of
patients in the safety population (167/220) had received
ESA therapy. Of the 106 patients who received
previous non-C.E.R.A. ESA therapy, this comprised
darbepoetin alfa [n = 72 (32.7 %)], epoetin beta
[n = 24 (10.9 %)], epoetin zeta [n = 15 (6.8 %)] and
epoetin alfa [n = 11 (5.0%)] (more than one ESA
therapy was possible). In total, 61 patients in the safety
population received C.E.R.A. prior to study entry. In
the modified efficacy population, 47 patients had pre-
viously received C.E.R.A.
3.2 C.E.R.A Administration
The mean (SD) dose of C.E.R.A. per application was 109
(57) lg throughout the study, equivalent to 3.5 (2.1)
lg/day [total cumulative dose 1,040 (625) lg]. The most
frequent initial doses were 50 lg (38/220, 17.3 %), 75 lg
(48/220, 21.8 %) and 100 lg (43/220, 19.5 %). The mean
dose of C.E.R.A. per application remained stable from
baseline [110 (63) lg] to month 9 [103 (61) lg]. During
the nine-month study period, 138 patients (62.7 %)
required one or more C.E.R.A. dose change, while the
remaining 82 patients (37.3 %) remained on their initial
dose. The proportions of patients receiving a dose increase
(106/220, 48.2 %) or a dose decrease (111/220, 50.5 %)
were similar, with a mean of 0.9 dose increases and 0.8
dose decreases per patient during the study. In total, the
mean (SD) number of dose changes per patient during the
study was 1.7 (1.8).
Of the 2,097 C.E.R.A. doses administered during the
study, 1,972 (94.0 %) were given subcutaneously and 92
(4.4 %) intravenously (route was unknown for 33 doses).
Doses were administered in the clinic (85/220 patients,
38.6 %), at home (78/220, 35.5 %) or both (57/220,
25.9 %).
The mean (SD) time between C.E.R.A. doses was 28.2
(7.2) days.
Fig. 1 Patient disposition.
C.E.R.A. continuous
erythropoietin receptor
activator, Hb hemoglobin, ESA
erythropoiesis stimulating agent
Table 1 Patient characteristics at study entry (safety population,
n = 220)
Age (years)
Mean (SD) 56.9 (15.1)
Median (range) 61 (19–93)
Male [n (%)] 113 (51.4)
Body mass index (kg/m2)
Mean (SD) 26.0 (4.6)
Median (range) 25.5 (13.7–48.5)
Caucasian [n (%)] 215 (96.4)
Concomitant conditions [n (%)]
Cardiac disorders 90 (40.9)
Diabetes mellitus (type 2) 40 (18.2)
Duration of peritoneal dialysis (years)
Mean (SD) 3.0 (2.1)
Median (range) 2.0 (1–15)
Type of peritoneal dialysis [n (%)]




Mean (SD) 9.9 (12.5)
Median (range) 7.0 (1.2–76.5)
C-reactive protein (mg/L)
Mean (SD) 7.2 (9.0)
Median (range) 5.2 (0.5–40.0)
Hb (g/dL)
Mean (SD) 11.1 (1.3)
Median (range) 11.1 (5.4–15.7)
eGFR estimated glomerular filtration rate, Hb hemoglobin, SD stan-
dard deviation
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3.3 Efficacy
Mean (SD) Hb level was 11.1 (1.4) g/dL at baseline and
11.5 (1.3) g/dL at the end of the study (modified efficacy
population) (Fig. 2). A small initial rise after study entry
was attributed to the 53 patients who were not previously
receiving ESA therapy prior to study, in whom mean (SD)
Hb increased from 11.0 (1.4) g/dL at baseline to 11.5
(1.4) g/dL one month after initiation of C.E.R.A. therapy
and 11.3 (1.5) g/dL at month 9. For the 106 patients who
were receiving non-C.E.R.A. ESA treatment prior to the
study, mean (SD) Hb level was 11.3 (1.3) g/dL at baseline,
11.5 (1.2) g/dL after one month and 11.7 (1.0) g/dL at
month 9.
Figure 3 illustrates the proportion of patients with all
available Hb values within pre-specified ranges during the
evaluation phase. The proportion of patients in the range
11–12 g/dL during the evaluation phase, i.e. the primary
efficacy variable, was 18.4 % (34/185) of patients in the
efficacy population for whom Hb measurements were
provided, and 14.8 % (24/162) in the modified efficacy
population. During the evaluation phase, approximately
40 % of patients in the efficacy and the modified efficacy
populations had all measured Hb levels within the 10–12 or
11–13 g/dL ranges (Fig. 3). Among the 115 patients in the
modified efficacy population who did not receive C.E.R.A.
prior to study entry, 13.9 % (16/115), 38.3 % (44/115) and
38.3 % (44/115) had all Hb values within the ranges 11–12,
10–12 and 11–13 g/dL, respectively. During the evaluation
period, approximately 83 % of patients had all Hb values
C10 g/dL and 87 % of patients had all Hb values B13 g/dL
in both the efficacy and modified efficacy populations
(Fig. 3).
The mean (SD) maximum intra-individual fluctuation
in Hb level during the evaluation period was 0.56
(0.50) g/dL in the efficacy population and 0.58 (0.49) g/dL
in the modified efficacy population. The maximum intra-
individual fluctuation during the evaluation phase was
B1 g/dL in 85.4 % (158/185) and 83.3 % (135/162) of
patients in the efficacy and modified efficacy populations,
respectively.
3.4 Safety and Tolerability
No adverse drug reactions were reported during the study.
No clinically relevant changes in laboratory values or vital
signs were noted during the study.
4 Discussion
In this large population of maintenance peritoneal dialysis
patients, once-monthly administration of C.E.R.A.
achieved a high degree of Hb stability and was well-tol-
erated when administered according to local practice.
Conversion from more frequently-administered ESA ther-
apies to C.E.R.A.—or introduction of C.E.R.A. as de novo
therapy—proved convenient, with relatively few doses
changes and approximately 65 % of patients administering
at least one dose at home.
Maintaining Hb levels within a narrow target range in
dialysis patients is notoriously challenging due to the
high degree of Hb variability observed in dialysis popu-
lations [32]. Indeed, one retrospective study in the
Fig. 2 Mean (SD) hemoglobin level in all patients, in patients
without any erythropoiesis stimulating agent (ESA) therapy prior to
study entry, and in patients who received an ESA therapy other than
continuous erythropoietin receptor activator (C.E.R.A.) prior to study
entry (modified efficacy population, n = 162)
Fig. 3 Proportion of patients within pre-specified hemoglobin (Hb)
ranges during the evaluation phase (months 6–8). The efficacy
population consisted of patients with at least one Hb value during the
evaluation phase (n = 185). The modified efficacy population
consisted of all patients in the efficacy population for whom at least
two Hb measurements were available during the evaluation period
(n = 162)
C.E.R.A. in Peritoneal Dialysis 703
Netherlands, which included 56 hemodialysis patients
and 12 peritoneal dialysis patients, found that none
remained within the target range of 11–12 g/dL over a
one-year period during ESA therapy [33]. The current
real-life population is likely to have included more
challenging patients than in randomized controlled trials
which, for example, frequently specify a baseline Hb
range and maximum limits for Hb fluctuation as part of
the inclusion criteria. Against this background, the find-
ing that only approximately 15 % of patients in the
modified efficacy population achieved the primary vari-
able of all Hb levels within 11–12 g/dL during the three-
month evaluation phase is not unexpected. Perhaps more
relevantly, few patients had Hb values \10 g/dL
(approximately 17 %). Importantly, only 13 % had a
single Hb value above 13 g/dL during the evaluation
period, consistent with recent recommendations from
KDIGO [9].
The initial doses of C.E.R.A prescribed by the
managing physicians were appropriate, as indicated by
the largely unchanged mean dose and the similar pro-
portion of dose increases and dose decreases during the
study. Multicenter studies in which hemodialysis
patients were converted from shorter-acting ESA prep-
arations to monthly C.E.R.A. have reported similar
findings [20, 34]. It is encouraging that almost 40 % of
patients required no dose changes over the 9-month
study, with an overall mean of fewer than two dose
changes per patient. This is consistent with findings
from a pooled analysis of three comparative Phase III
trials of C.E.R.A. twice- or once-monthly versus
shorter-acting ESAs in hemodialysis patients, in which
significantly fewer dose changes were required in the
C.E.R.A. treated patients [35], and previous observa-
tional data in peritoneally dialyzed patients [36]. More
frequent ESA dose changes show an association with
increased Hb fluctuation [33, 36], a relationship that
appears to be causal [36], so a low rate of dose alter-
ations may support stable Hb control. Data from dial-
ysis populations [37, 38] have suggested that fluctuation
from target Hb range to values below 11 g/dL are
associated with increased mortality. Here, the mean
fluctuation in Hb levels over the nine-month study was
*1.5 g/dL, which compares favorably with published
data [33]. A retrospective, single-center analysis
reported a trend to fewer excursions from Hb target
range in C.E.R.A.-treated peritoneal dialysis patients
versus those receiving epoetin beta, although complete
Hb cycles were similar in both groups [36]. The authors
concluded that fewer dose changes with C.E.R.A. may
offer a small advantage in reducing the degree of Hb
variability [36].
Another 9-month observational study with a similar
protocol has been conducted in 924 hemodialysis patients
[20]. Baseline Hb levels were broadly similar to the current
population [mean (SD) 11.4 (1.2) g/dL compared to 11.1
(1.3) g/dL here] [20]. During the evaluation phase in the
hemodialysis patients, Hb parameters were consistently
similar to those seen in the current peritoneal dialysis
population, including mean Hb levels, the proportion of
patients within pre-specified Hb ranges, the mean intra-
individual Hb fluctuation and the proportion of patients
with a maximum intra-individual fluctuation B1 g/dL. In
the hemodialysis patients, however, the mean dose of
C.E.R.A. over the nine-month study was 124 lg compared
to 109 lg in the current peritoneal dialysis population.
Carrera et al. [39] described an initial mean C.E.R.A. dose
of 159 lg, titrated upwards by protocol to 260 lg. These
data are in line with published data showing that higher
ESA doses are often required in hemodialysis patients to
achieve the same level of Hb control as in peritoneally
dialyzed patients [21–25].
With regards the safety profile of C.E.R.A., no adverse
drug reaction was reported in this series of over 200
patients during the eight-month period.
5 Conclusions
Once-monthly C.E.R.A. was effective and well-tolerated
when used in routine clinical practice for the treatment of
anemia in peritoneal dialysis patients either following con-
version from more frequently-dosed ESA therapies or as de
novo treatment. Results in this largely unselected population
of peritoneally dialyzed patients suggest that the effective-
ness of once-monthly C.E.R.A. in peritoneally dialyzed
patients is similar to that observed in hemodialysis patients
but that this may be achieved at a slightly lower dose.
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